Encapsulating peritoneal sclerosis in an Italian center: thirty year experience
- 211 Downloads
Encapsulating peritoneal sclerosis (EPS) is a rare but life-threatening complication of peritoneal dialysis (PD). Its incidence and prevalence are still not clearly defined. No data exist on the prevalence of EPS in Italy.
To evaluate the incidence and prevalence of EPS, and identify potential factors useful for prevention or early diagnosis of EPS.
A retrospective study in patients starting PD between 1979 and 2013 in one Italian center. Data on demographics, occurrence of EPS, time on PD, peritoneal equilibration test, and therapy for EPS were gathered.
EPS occurred in 26/920 patients with a prevalence of 2.8 % and incidence of 1/105 patient-years. The prevalence increased with the time spent on PD: 0.4 % for PD duration <2 years, 3 % (2–4 years), 4 % (4–6 years), 6 % (6–8 years), 8 % (8–10 years), 18 % (10–12 years), 75 % (12–14 years), 67 % (>14 years). EPS prevalence was not higher in PD patients transplanted: 5/172 (2.9 %); only two of them (1.2 %) were diagnosed while with a functioning graft. In only one patient (0.6 %) was the diagnosis made during hemodialysis; the other 23 were diagnosed while still on PD. Mortality due to EPS was 38.5 %, and was associated with PD duration. Therapy with steroids reduced mortality [hazard ratio 0.047 (95 % CI: 0.008–0.273); p < 0.001].
In our experience the prevalence of EPS is low, but increases progressively with the duration of PD. The transfer to hemodialysis or transplantation does not appear to be a key factor for EPS. Therapy with steroids significantly improves the outcome.
KeywordsEncapsulating peritoneal sclerosis Peritoneal dialysis Abdominal cocoon Peritonitis Dialysis
Compliance with ethical standards
Conflict of interest
All the authors disclose no conflict of interest with the topic and the content of this paper.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
For this type of study formal consent is not required.
- 1.Kawanishi H, Moriishi M (2005) Epidemiology of encapsulating peritoneal sclerosis in Japan. Perit Dial Int 25(Suppl 4):S14–S18Google Scholar
- 2.Kawaguchi Y, Kawanishi H, Mujais S, et al (2000) Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International society for peritoneal dialysis ad hoc committee on ultrafiltration management in peritoneal dialysis. Perit Dial Int 20(Suppl 4):S43–S55Google Scholar
- 3.Pollock CA (2001) Diagnosis and management of encapsulating peritoneal sclerosis. Perit Dial Int 21(Suppl 3):S61–S66Google Scholar
- 4.Garosi G, Di Paolo N (2001) Morphological aspects of peritoneal sclerosis. J Nephrol 14(Suppl 4):S30–S38Google Scholar
- 21.Chang AR (1980) Test and teach. Number twenty-one. Diagnosis: practolol induced sclerosing peritonitis. Pathology 12:32–33, 131–133Google Scholar
- 24.Korte MR, Sampimon DE, Betjes MG et al (2011) Encapsulating peritoneal sclerosis: the state of affairs. Nat Rev Nephrol 2:528–538Google Scholar
- 30.de Vos Tot Nederveen Cappel WH, Dubbeld J, Willems SM et al (2008) Liver transplantation in a patient with encapsulating peritoneal sclerosis. Neth J Med 66:280–282Google Scholar
- 39.Park SH, Kim YL, Lindholm B (2008) Experimental encapsulating peritoneal sclerosis models: pathogenesis and treatment. Perit Dial Int 28(Suppl 5):S21–S28 [Erratum in: Perit Dial Int 2009; 29: 131–132] Google Scholar